Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure

Clinical trial NCT02997995 · COMPLETED

Trial details

NCT number: NCT02997995
Sponsor: UNICANCER
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Breast Cancer Estrogen Receptor Positive Tumor Menopause Hormone Antagonist

Start date: 2017-02-15
Primary completion: 2019-07-15
Enrollment: 61

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.